Liso-cel shows promise as a new treatment for relapsed or refractory CLL/SLL, while olaparib rechallenge improves progression-free survival in ovarian cancer patients regardless of BRCA status.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
The Targeted Pulse: Breakthrough Treatments in Blood Cancers, Ovarian Cancer, and More | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Relapsed Or Refractory CLL/SLL Treatment target
Improved Progression-Free Survival With Olaparib Rechallenge Ovarian cancer benefit
Phase 3b OReO/ENGOT-Ov38 Study phase